Tvardi Therapeutics (TVRD) Stock Price & Analysis
TVRD Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 9.07M
- Enterprise Value
- CHF 2.20M
- Total Cash (Recent Filing)
- CHF 15.77M
- Total Debt (Recent Filing)
- CHF 145.00K
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.47
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Current Debt
Minimal current debt reduces interest and refinancing pressure, preserving more financial flexibility for clinical development. Although the balance sheet has historical weaknesses, the present leverage profile does not appear to be the main constraint on funding near-term operating priorities.
Reduced Loss And Cash Burn
The reduction in losses and cash usage is a constructive operating trend that could extend the company’s runway relative to earlier periods. Continued improvement would make future financing needs more manageable, even though the business still consumes substantial cash and has not reached self-funding.
Clinical Progress And Focus
Early clinical evidence of target engagement and improved tolerability supports the scientific rationale for the STAT3-focused pipeline. Selecting an initial indication also creates a clearer development path, potentially concentrating resources and improving execution over the next several quarters.
Bears Say
Revenue Has Fallen To Zero
The disappearance of reported revenue leaves the company without demonstrated recurring commercial inflows to support operations. Until revenue returns, funding for development must depend on existing resources or external capital, making progress more vulnerable to financing conditions and execution setbacks.
Persistent Cash Consumption
Sustained negative operating and free cash flow means the company is not currently financing its activities internally. Ongoing burn can reduce available resources and require additional funding to maintain development programs, potentially limiting strategic flexibility if capital needs remain elevated.
Shrinking Assets And Balance-Sheet History
The sharp asset decline indicates a smaller financial base from which to fund clinical operations, while prior periods of negative equity demonstrate balance-sheet instability. Together, these factors reduce resilience and leave less capacity to absorb delays, setbacks, or continued operating losses.
Tvardi Therapeutics News
TVRD FAQ
What is Tvardi Therapeutics’s market cap?
When is Tvardi Therapeutics’s upcoming earnings report date?
How were Tvardi Therapeutics’s earnings last quarter?
Is Tvardi Therapeutics overvalued?
Does Tvardi Therapeutics pay dividends?
What is Tvardi Therapeutics’s EPS estimate?
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tvardi Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Imran Alibhai
- Employees
- 12
- Website
- tvarditherapeutics.com
- Address
- 3 Sugar Creek Center Boulevard, Sugar Land, TX, 77478, US
Tvardi Therapeutics (TVRD) Earnings & Revenues
TVRD Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted a strategic focus on a promising NP program with potential for significant clinical and commercial success. However, challenges with KORSUVA revenue and increased R&D expenses were notable concerns.
View all CH:TVRD earnings summaries